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SIRT1, a NAD+-dependent protein deacetylase that regulates transcription factors involved in key cellular
processes, has been implicated as amediator of the beneficial effects of calorie restriction. In a recent issue of
Nature, Milne et al. (2007) describe novel potent activators of SIRT1, whose administration to insulin-resistant
animals improves glucose homeostasis.Chronic consumption of an energy-rich
diet, combined with a sedentary lifestyle,
increases the risk of cardiovascular dis-
ease, type 2 diabetes, and cancer. Nu-
merous studies in humans have shown
that decreasing calorie intake reduces
markers of metabolic disorder such as
blood glucose, cholesterol, and blood
pressure. If low-calorie diets could be
sustained, they would undoubtedly re-
duce age-related chronic diseases and
significantly extend life span. However,
despite this knowledge, the global rise in
obesity and type 2 diabetes suggests
that most individuals in modern society
struggle to put modest eating into prac-
tice. There has therefore beenmuch inter-
est in developing pharmacological agents
that mimic the effects of calorie restric-
tion. Such drugs could provide the desir-
able physiological outcomes of caloric
restriction without the necessity of under-
taking rigorous dietary and weight-loss
programs.
Recently, growing evidence has indi-
cated that red wine might serve as a calo-
rie restriction mimetic. Studies have
shown that resveratrol (Cucciolla et al.,
2007), a natural compound found in the
skin of red grapes, activates SIRT1,
a NAD+-dependent protein deacetylase.
This activation increases the survival of
mice fed a high-calorie diet by ameliorat-
ing their metabolic and physiological dis-
turbances (Baur et al., 2006; Lagouge
et al., 2006). Based on the dose of res-
veratrol used in this experiment and
the concentrations found in red wine,
humans would probably need to drink
300 glasses of wine per day to receive
an equivalent dose (Kaeberlein and Rabi-
novitch, 2006). Of course, the question
arises of whether there is a way to activateSIRT1 without having to drink that much
wine. In a recent issue of Nature, Milne
et al. (2007) report the identification and
characterization of novel small-molecule
activators of SIRT1 that are 1000-fold
more potent than resveratrol. Short-term
administration of these compounds re-
verses many of the metabolic abnormali-
ties in animal models of obesity and type
2 diabetes, implicating SIRT1 activators
as potential drug treatments for metabolic
diseases.
Milne et al. screened a large selection of
small molecules (a total of 290,000 com-
pounds) and found 172 potential SIRT1
activators that are structurally unrelated
to resveratrol. After chemical optimiza-
tion, three compounds were used for
functional analyses, and it was confirmed
that these small molecules are able to cat-
alyze the deacetylation of p53, a well-es-
tablished SIRT1 substrate, in intact cells.
This effect was abolished in the presence
of a selective SIRT1 inhibitor. The authors
found that the novel SIRT1 activators ex-
ert their effects by increasing SIRT1 bind-
ing capacity for acetylated substrates
(Figure 1). Moreover, the SIRT1 activators
bind to a noncatalytic region on the amino
terminus of SIRT1. Interestingly, resvera-
trol also activates SIRT1 in a similar man-
ner. It will be informative to crystallize the
amino-terminal domain of SIRT1 com-
plexed to activating drugs, which could
give insight into developing even more
potent SIRT1 activators.
In order to test whether these com-
pounds have therapeutic potential for the
treatment of metabolic disorders, mice
were placed on a high-fat diet (60% of
calories from fat), which is commonly
used to promote obesity and insulin re-
sistance, and were orally administeredCell MetabSIRT1 activators (100 mg/kg body
weight/day) or vehicle. Notably, 2 weeks
of drug treatment resulted in a reduction
of postprandial blood glucose levels by
30% (200 mg/dl to 140 mg/dl), and
10 weeks of treatment improved glucose
homeostasis as evidenced by an increase
in the rate of glucose disposal when mice
were challenged with a bolus of glucose
or with insulin injection. In line with the
proposed role of SIRT1 in regulation of
mitochondrial biogenesis through PGC-
1a (Rodgers et al., 2007), drug treatment
resulted in increased expression of a key
mitochondrial enzyme, citrate synthase.
The authors next employed a genetic
model of type 2 diabetes, the leptin-
deficient ob/ob mouse, and found that
SIRT1 activators reduced blood glucose
to almost normal levels (120–200 mg/dl)
within 1 week. Reformulated resveratrol
with improved bioavailability required a
10-fold higher dose (1000 mg/kg body
weight) to obtain equivalent glucose-
lowering effects. Finally, the drugs were
tested with another model of type 2
diabetes, the Zucker diabetic fatty (ZDF)
fa/fa rat, and this confirmed that the
SIRT1 activators improve whole-body
glucose homeostasis as a result of en-
hancing insulin sensitivity in key meta-
bolic tissues, including muscle, fat, and
liver.
Although SIRT1 activators ameliorate
metabolic abnormalities in multiple insu-
lin-resistant animals, surprisingly, it was
not shown whether administration of
SIRT1 activators to mice induces deac-
etylation of key SIRT1 substrates, such
as PGC-1. Several other aspects of these
compounds remain to be explored, in-
cluding their chronic effects on life span,
metabolic capacity, muscle and heartolism 7, January 2008 ª2008 Elsevier Inc. 3
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PreviewsFigure 1. Mechanism by which Small Molecules Regulate SIRT1 Activity and Subsequent
Biological Processes
Binding of SIRT1 activators (resveratrol and SRT1720, from Milne et al. [2007]) to the noncatalytic amino-
terminal region (allosteric domain) of SIRT1 enhances binding capacity toward the acetylated substrates,
which promotes a more productive conformation that enhances deacetylation activity. SIRT1 uses cofac-
tor NAD+ during the deacetylation reaction, transferring the acetyl group (AC) on lysine residues (Lys) from
the substrate proteins to the ribose sugar, thereby producing 2-O-acetyl-ADP-ribose and nicotinamide.
Deacetylation of a key substrate such as PGC-1 is proposed to stimulate genes for oxidative phos-
phorylation, leading to enhanced mitochondrial function and consequently improving insulin sensitivity.
+ represents activation of SIRT1 activity by SIRT activators.function, and food intake. It should also
be noted that specificity of these com-
pounds toward panels of other deacety-
lases, receptors, and/or protein kinases
has not been described. Therefore, it is
possible that the effects of SIRT1 activa-
tors could be mediated in part though
other targets.
A major question that requires further
investigation is whether SIRT1 activation
is necessary and/or sufficient for the
SIRT activators’ effects or whether other
targets are required to mediate their ben-
eficial effects. It is intriguing that SIRT1
activators mimic many of the effects of
AMP-activated protein kinase (AMPK)
activation. AMPK is an energy sensor
that monitors the cellular AMP:ATP ratio
and becomes activatedwhen cells are ex-
posed to energy-depleting stresses such4 Cell Metabolism 7, January 2008 ª2008 Eas hypoxia or muscle contraction (Hardie
and Sakamoto, 2006). AMPK activation
restores energy balance by stimulating
muscle glucose uptake and enhancing
insulin sensitivity in tissues, including fat
and liver, and AMPK-activating drugs
such as metformin mimic these effects
(Hardie, 2007). Several recent studies
have suggested that resveratrol stimu-
lates AMPK (Baur et al., 2006; Dasgupta
and Milbrandt, 2007). It will therefore be
important to establish whether the novel
SIRT1 activators stimulate AMPK and, if
so, whether SIRT1 and AMPK cooperate
to enhance insulin sensitivity and reverse
metabolic abnormalities. Currently, there
is no evidence indicating whether the ef-
fects of SIRT1 activators are mediated
through AMPK or whether the effects
of AMPK activators require SIRT1. Tolsevier Inc.address this question, one approach
would be to see whether the effects of
SIRT1 activators are abolished in mice
withmuscle- and/or liver-specific deletion
of SIRT1 and/or the catalytic subunits of
AMPK. Furthermore, mice with muscle-
or liver-specific deletion of PGC-1a could
be used to determine whether the effects
of SIRT1 activators require PGC-1a.
It is becoming clear that disruption of
cellular energy metabolism is a common
source of age-related diseases and that
exposing organisms to low-energy states
that activate AMPK and/or SIRT1, such as
calorie restriction and exercise, can ame-
liorate abnormal energy balance. Novel
activators of SIRT1 and/or AMPK there-
fore hold considerable promise as drugs
aimed at treating metabolic diseases.
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